Call for Responses
The case outlined below, will be the basis for the In That Case section for the next issue of the New Zealand Bioethics Journal. We invite interested readers to provide commentaries for possible publication. Responses should be kept to approximately 500-700 words in length. The editorial board will select the responses to be published in the October, 2001 issue of the New Zealand Bioethics Journal. We also reserve the right to edit contributions, to avoid repetition of points for example. All editorial changes will be cleared with the authors before going to press. Contributions can be sent by email or by posting a copy to the Editor. Please include your name, address and phone number with your response.

Your company has invested heavily in developing an AIDS vaccine and wishes to embark on clinical trials. Applications have been made to numerous ethics committees in your developed country but all have refused approval on the basis that the risks of infection for the research participants are too great. You have learned of researchers in a sub-Saharan country who are keen to take up the research for your laboratory at a price which seems very reasonable to you in terms of research and development. The city in which the research would be conducted has 33% plus instance of HIV positive citizens. Its death toll from AIDS is already very high. Diarrhoea is the major cause of death in that country, by a factor of four followed by malaria. The country has no system of ethical review. What should you do?